Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Inventory (2023 - 2025)

Krystal Biotech (KRYS) has disclosed Inventory for 3 consecutive years, with $40.5 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 52.69% to $40.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.5 million through Dec 2025, up 52.69% year-over-year, with the annual reading at $40.5 million for FY2025, 52.69% up from the prior year.
  • Inventory hit $40.5 million in Q4 2025 for Krystal Biotech, up from $37.6 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $40.5 million in Q4 2025 to a low of $5.3 million in Q3 2023.
  • Historically, Inventory has averaged $22.0 million across 3 years, with a median of $22.5 million in 2024.
  • Biggest five-year swings in Inventory: skyrocketed 279.5% in 2024 and later soared 52.69% in 2025.
  • Year by year, Inventory stood at $7.0 million in 2023, then surged by 279.5% to $26.5 million in 2024, then skyrocketed by 52.69% to $40.5 million in 2025.
  • Business Quant data shows Inventory for KRYS at $40.5 million in Q4 2025, $37.6 million in Q3 2025, and $31.0 million in Q2 2025.